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Abstract
Individuals who are chronically infected with the hepatitis B virus (HBV) are highly heterogenous with respect to serum
levels of HBV DNA, HBV particles and viral proteins. Since circulating leukocytes, such as monocytes, are constantly exposed
to these viral components, it is likely that the functionality of these cells is affected. However, at present, little information is
available on the consequences of the interaction between monocytes and viral components. Therefore, we examined the in
vitro effects of HBV surface antigen (HBsAg) on monocytes and evaluated whether these effects were reflected in vivo. We
observed that in vitro HBsAg exposure of monocytes induced robust production of IL-6 and TNF. However, between chronic
HBV patients with distinct levels of serum HBsAg, HBV early antigen (HBeAg), and HBV DNA, TLR-induced monocyte
cytokine production did not differ. Importantly, HBsAg-induced cytokine production by monocytes was similar between
patients and healthy controls showing that earlier in vivo exposure to HBsAg does not affect the in vitro response.
Additionally, we show that IL-10 is able to inhibit cytokine production by HBsAg-induced monocytes. In conclusion, we
demonstrate that monocytes can recognize and respond to HBsAg, resulting in vigorous pro-inflammatory cytokine
production in vitro. However, phenotype and function of the monocyte compartment in chronic HBV patients are not
influenced by differences in levels of serum viral components, suggesting that regulatory mechanisms are active to avoid
excessive in vivo monocyte activation.
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Introduction
Hepatitis B virus (HBV) infection is a major health problem.
Although the majority of infected individuals clear the virus
spontaneously, a fraction of patients is unable to clear the virus
and develops a chronic form of hepatitis. Their numbers have
already reached over 240 million people [1]. In time, persistence
of HBV can lead to progressive liver damage, which increases the
patient’s risk of developing liver cirrhosis, liver failure and liver
cancer. Chronicity of HBV is the result of a complex interaction
between the replicating virus and an inadequate immune response
[2–4]. After infection, viral replication takes place inside hepato-
cytes, and the secretion of infectious virions can take place for
decades at high rates, and consequently HBV DNA, as well as
viral proteins, like HBV early antigen (HBeAg) and HBV surface
antigen (HBsAg), can be easily detected in serum. The levels of
these clinical markers may fluctuate over time and are a reflection
of disease activity and commonly used to define the patients’
disease stage [3,4].
Although circulating monocytes represent about 10% of
leukocytes in human blood, relatively little is known on the
consequences of chronic viral infections on monocytes. In HIV
infections impaired monocyte functions have been reported [5,6],
and we recently demonstrated altered Toll-like receptor (TLR)
responsiveness of monocytes obtained from patients with chronic
HCV infections [7,8]. Monocytes can be divided into two distinct
subpopulations that are discerned based on their surface
expression of CD14 and CD16. CD14highCD162 monocytes
make up the majority (80–90%) of blood monocytes, and have
been reported to produce relatively high IL-10 and weak TNF
levels, whereas the CD14+CD16+ subpopulation produces higher
levels of pro-inflammatory cytokines, such as TNF and IL-1b
[9,10].
Also in chronic HBV, some studies reported modulation of the
monocyte compartment as a result of the disease. Depending on
the clinical phase of the chronic HBV infection altered monocyte
subsets frequencies were reported [11,12]. Moreover, PBMC from
HBeAg-positive patients produced less TNF and IL-6 upon
stimulation with TLR2 agonists as compared to HBeAg-negative
patients [13], which was explained by lower expression of TLR2 in
HBeAg-positive patients [14]. Furthermore, exposure of mono-
cytes to HBsAg suppressed LPS-induced TNF and IL-1b
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production [15], while others reported that HBsAg has an
immunostimulatory effect by inducing TNF and IL-10 production
[16]. Since the consequences of constant exposure of peripheral
monocytes to viral particles and the viral proteins HBeAg and
HBsAg are still not completely understood, we here studied the in
vitro and in vivo effects of these molecules on the phenotype and
function of peripheral monocytes.
Materials and Methods
Patients and ethics statement
Peripheral blood was collected from patients chronically
infected with HBV who visited the outpatient clinic of the
Erasmus Medical Center. Patients eligible for the study were
positive for HBsAg, and were not on-treatment before blood
samples were taken for this study. Patients co-infected with human
immunodeficiency virus, hepatitis A virus, hepatitis C virus or
hepatitis D virus were excluded. Patient characteristics are
presented in Table 1. The medical ethical committee of the
Erasmus MC University Medical Center approved the study and
all patients gave written informed consent before inclusion.
Laboratory measurements
HBsAg levels and HBeAg levels were measured in sera from a
total of 45 chronic HBV patients using the Architect HBsAg assay
(Abbott Laboratories, Abbott Park, IL, USA; range 0.05–250 IU/
ml) or HBeAg assay (Abbott Laboratories; interpreted using a ratio
of the sample relative light unit (RLU) rate to the cut-off RLU (S/
CO)). HBV DNA levels were measured in serum using the Cobas
TaqMan (Roche Diagnostics; lower limit of quantification, 20 IU/
ml). ALT was measured as part of standard diagnostic procedures.
HBV genotype was determined by means of the INNO-LiPA
assay (Innogenetics, Gent, Belgium).
Flow cytometric analysis of monocyte subpopulations
To determine the frequencies of monocyte subpopulations,
whole blood was lysed and stained with antibodies against CD14
and CD16 (61D3 and 3G8, respectively; both eBioscience, San
Diego, CA, USA), and measured by flow cytometry using a BD
FACSCanto II (BD Biosciences, San Diego, CA, USA). Data was
analyzed using FlowJo 7.6.5 software (Tree Star, Inc., Ashland,
OR, USA).
Monocyte stimulation and ELISA
Peripheral blood was collected from chronic HBV patients or
healthy controls in sodium-heparin tubes, and PBMC were
isolated by Ficoll-Paque (GE Healthcare, Uppsala, Sweden)
gradient centrifugation, and frozen. PBMC (16106 cells/ml) were
thawed and stimulated in 96-well plates in 250 ml X-VIVO culture
medium (Lonza, Verviers Sprl, Belgium) containing penicillin/
streptomycin (Gibco, Paisley, UK), L-glutamin (Lonza), and
HEPES (Lonza) as described previously [7]: the cells were cultured
either unstimulated or stimulated with 100 ng/ml Toll-like
receptor (TLR) 2 ligand Pam3CSK4, 100 ng/ml TLR4 ligand
LPS (both from Invivogen), 1 mg/ml TLR7/8 ligand R848 (Enzo
Life Sciences, Antwerp, Belgium), or human plasma-derived
pHBsAg Ay (American Research Products (ARP), Waltham,
MA, USA) at a concentration of 5 mg/ml unless mentioned
otherwise. In the experiment shown in Figure S1, in parallel to
plasma-derived HBsAg Ay (5 mg/ml) stimulation, PBMC were
also stimulated with recombinant HBsAg (1 mg/ml; Prospec,
Rehovot, Israel) for 5 hours. In the IL-10 inhibition experiment,
10 ng/ml IL-10 (Miltenyi Biotec, Bergisch Gladbach, Germany)
or medium as a negative control, was added at the same time as
pHBsAg (1 mg/ml; ARP). After a total of 18 hours of culture,
supernatants were harvested, and cytokine production (IL-6 and
TNF) was determined by ELISA (all kits from eBioscience).
Intracellular cytokine staining
The frequency of cytokine-producing monocytes was deter-
mined by measuring cytokines with intracellular cytokine staining
using flow cytometry. PBMC were stimulated with TLR ligands or
pHBsAg Ay (ARP) as described above, After culturing for 2 hours,
brefeldin A (10 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) was
added to all wells. After 16 hours, the cells were harvested,
incubated with LIVE/DEAD Fixable Aqua Dead Cell Stain
(Invitrogen, Ltd., Paisley, United Kingdom), fixed with 2%
formaldehyde, permeabilized with 0.5% saponin (VWR, West
Chester, PA, USA) and stained for IL-6 (MQ2-13A5; eBioscience),
and TNF (Mab11; eBioscience), and the surface markers CD14
and CD45 (61D3 and HI30, respectively; both eBioscience). Flow
cytometric data was acquired and analyzed as described above.
Statistical analysis
To compare clinical groups, groups were analyzed using the
non-parametric Kruskal-Wallis test, followed by Dunn’s multiple
comparisons test. The frequencies of cytokine-producing cells
determined at different HBsAg doses were normalized to the
values obtained under the 1 mg/ml HBsAg condition. Differences
between the cytokine expression of the healthy individuals and the
group with chronic HBV patients were analyzed using the Mann-
Whitney U test. A P-value of ,0.05 was considered statistically
significant. Graphpad Prism 5 was used for statistical analysis.
Table 1. Patient characteristics.
Group 1 Group 2 Group 3
Number 14 20 11
Sex (F:M) 5:9 11:9 6:5
Age 41.1 (24–59)a 35.1 (20–53) 31.4 (18–48)
ALT (IU/L) 83 (21–366) 37 (15–102) 111 (22–443)
Viral load (IU/mL) 63.86106 (28,300–6.06108) 1,767 (20–6,490) 1.06109 (29,200–2.66109)
HBeAg level (IU/mL) 7.96 (0–66.65) 0.17 (0–2.38) 944 (389–3,259)
HBsAg level (IU/mL) 10,341 (56–31,660) 3032 (108–17,448) 53,581 (542–125,820)
aValues for age, ALT, viral load, HBeAg level and HBsAg level are mean (minimum – maximum value).
doi:10.1371/journal.pone.0097006.t001
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Results
HBsAg induces cytokine production by monocytes in
vitro
To investigate the modulatory effect of HBsAg on the
functionality of blood monocytes, PBMC from healthy individuals
were cultured in the presence of HBsAg. We compared
monocytes, defined in Figure 1A as CD45 and CD14-expressing
cells with their characteristic FSC and SSC profile, after overnight
culture with either medium or HBsAg. As shown in Figure 1B and
quantified in Figure 1C, the frequency of cytokine-producing
monocytes was increased upon exposure to HBsAg in vitro. Upon
exposure to HBsAg in vitro, the mean frequency of IL-6 and TNF-
producing monocytes was increased from 2.6% to 61% and from
3.5% to 59%, respectively (Figure 1C). The percentages of
monocytes producing IL-12p40, IL-15, and IL-10 were relatively
low, while the chemokines CCL4 and CXCL8 were strongly
induced (data not shown).
The ratio of monocyte subpopulations is comparable in
chronic HBV patients with different levels of HBV DNA or
serum HBV protein levels
The stimulatory effect of HBV proteins on blood monocytes
upon exposure in vitro may have consequences for the functionality
of the monocyte compartment in patients chronically infected with
HBV. To examine this, we selected groups of chronic HBV
patients differing in the levels of HBV DNA, HBeAg, and HBsAg.
As shown in Figure 2A, three groups were identified based on
HBV DNA and HBeAg levels. The experimental groups differed
not only in the levels of HBV DNA and HBeAg, but also in
HBsAg levels (Figure 2B). We defined group 1 as having low or
undetectable HBeAg levels, and intermediate HBV DNA levels
and HBsAg levels; group 2 as having low or undetectable HBeAg,
and low HBV DNA and HBsAg levels; group 3 as having high
levels of HBeAg, HBV DNA and HBsAg (Figure 2; Table 1).
Patient groups did not differ with respect to age or gender.
Monocytes can be divided on the basis of their expression of
CD14 and CD16, and these subpopulations have been reported to
Figure 1. HBsAg induces cytokine production by monocytes. PBMC from healthy individuals were stimulated with HBsAg. After overnight
incubation, cells were stained for CD14, IL-6 and TNF. (A) Gating strategy: Viable monocytes were identified on the basis of their forward-sideward
scatter profile and their membrane expression of CD14. (B) Representative intracellular cytokine stainings are presented showing IL-6 and TNF-
producing monocytes upon incubation with medium and HBsAg. (C) The frequencies of monocytes producing IL-6 or TNF upon incubation with
medium or HBsAg are presented (n = 9, ** p,0.01, Wilcoxon signed rank test).
doi:10.1371/journal.pone.0097006.g001
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exert distinct functions [9,10]. To examine whether the chronic
HBV patients in group 1, 2 and 3 differed in monocyte
composition, we first determined the frequency of the monocytes
expressing CD14 and CD16 in fresh peripheral blood samples
from patients. As shown in Figure 3, the ratio of CD14++CD16-
and CD14+CD16+ monocytes did not differ between the distinct
patient groups, indicating that chronic exposure to different
amounts of HBV DNA, HBsAg and HBeAg did not lead to
changes in the composition of the monocyte compartment.
Monocyte function does not differ between HBV patient
groups
Since we showed that in vitro exposure of monocytes to HBsAg
strongly induced the production of IL-6 and TNF, we explored
whether the function of monocytes was affected by continuous
exposure of monocytes to viral proteins in patients. To examine
this, PBMC obtained from the patients with distinct serum HBV
DNA, HBeAg and HBsAg levels were incubated overnight with
medium or the TLR2 ligand Pam3CSK4, the TLR4 ligand LPS,
or the TLR7/8 ligand R848, and cytokine production was
measured by intracellular cytokine staining and ELISA. A high
percentage of monocytes produced IL-6 and TNF after TLR
stimulation (Figure 4A and 4B). As shown in figure 4B, TLR
ligation of PBMC from chronic HBV patients with distinct serum
levels of HBV DNA, HBeAg and HBsAg resulted in similar
percentages of IL-6 and TNF producing monocytes. This was
observed for agonists against TLR2, TLR4 and TLR7/8.
Importantly, also the baseline frequencies of cytokine-producing
monocytes were not different between the three patient groups,
suggesting that circulating monocytes from patients were not at a
higher activation state as evidenced by spontaneous cytokine
secretion. Next, detailed data-analysis using SPICE software was
performed to evaluate the simultaneous production of multiple
cytokines by individual TLR-stimulated monocytes [17]. Again,
no differences were observed when comparing the patient groups
(data not shown). Besides frequencies, we also evaluated the
intensity of the fluorescent signals representing the amounts of
cytokines produced by monocytes upon stimulation, and also these
parameters were not different between the patient groups (data not
shown). In line with the above findings, also the amounts of TLR-
induced IL-6 and TNF produced by monocytes, as measured by
ELISA, were similar in the three groups of chronic HBV patients
that differed in their serum levels of HBV DNA, HBsAg and
HBeAg (Figure 4C).
Monocytes obtained from patients exposed in vivo to
distinct levels of HBV DNA, HBeAg and HBsAg, react
similarly to HBsAg stimulation in vitro
In contrast to the in vitro findings where exposure of monocytes
to HBsAg leads to high cytokine induction, comparison of
Figure 2. Chronic HBV patients divided into three groups based on HBV DNA and HBeAg levels. HBeAg levels, HBsAg levels and HBV
DNA were measured in 45 chronic HBV patients. (A) HBV patients were divided into an HBeAgnegative/HBeAglow group (,100 IU/ml), and an
HBeAghigh group (.100 IU/ml). Based on these two groups and HBV DNA levels, three groups of chronic HBV patients were defined (groups 1, 2 and
3). (B) Groups 1–3 were compared based on HBV DNA levels, HBeAg levels and HBsAg levels. *** p,0.0001, Kruskal-Wallis test, followed by Dunn’s
multiple comparison test.
doi:10.1371/journal.pone.0097006.g002
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circulating monocytes obtained from patients with different levels
of viral proteins in vivo, showed no higher spontaneous or TLR-
induced cytokine induction. One possible explanation could be
that continuous exposure of patient’s leukocytes to HBV proteins
makes them less sensitive to re-exposure. To examine this, we
compared the in vitro effects of HBsAg on monocytes obtained
from chronic HBV patients and from age- and sex-matched
healthy individuals. Exposure of PBMC from patients to HBsAg
resulted in IL-6 and TNF production, depicted by IL-6-positive
(86.162.0%) and TNF-positive (62.166.6%) CD14+ monocytes,
while also monocytes from healthy individuals were positive for IL-
6 (78.265.4%) and TNF (55.469.0%). Next, to examine whether
monocytes from patients and controls were equally sensitive to the
stimulatory effect of HBsAg, cells were stimulated with a dose-
range of the HBsAg protein. As shown in Figure 5, monocytes
from healthy controls and HBV patients were equally sensitive to
HBsAg at low, intermediate and high doses of HBsAg, and
consequently the responsiveness of monocytes to overnight HBsAg
stimulation was similar between both groups. Likewise, HBsAg
stimulation of PBMC for 5 hours, instead of 18 hours, also showed
similar frequencies of IL-6 and TNF-producing monocytes
between healthy controls and HBV patients, as shown in Figure
S1. This supplementary figure shows not only stimulation with
pHBsAg Ay as used throughout the paper, but also with
recombinant HBsAg, both resulting in no difference between the
groups. Also, assessment of overnight cytokine production by
ELISA confirmed that monocytes from healthy individuals and
from HBV patients react identical to HBsAg in terms of cytokine
production (data not shown).
IL-10 in vivo potently inhibits HBsAg-induced cytokine
production by monocytes
Having demonstrated that monocytes from chronic HBV
patients and healthy individuals are equally sensitive to HBsAg,
we considered the activity of immunosuppressive cytokines, such
as IL-10. In chronic HBV patients increased serum IL-10 levels
have been demonstrated by various research groups [18–22].
Enhanced production of this immunosuppressive cytokine and
increased sensitivity of activated monocytes to IL-10 may prevent
monocyte activation by HBsAg in vivo [23,24]. As depicted in
Figure 6, the presence of IL-10 clearly abrogated HBsAg-induced
cytokine production, demonstrating a possible in vivo mechanism to
curb HBsAg-induced cytokine production by monocytes.
Discussion
In the present study, we demonstrate that HBsAg has a potent
stimulatory effect on human monocytes upon in vitro culture.
However, detailed comparison of monocytes obtained from
chronic HBV patients showed that the differences in viral load,
Figure 3. Different HBV DNA, HBeAg and HBsAg levels do not alter the frequency of monocyte subpopulations.Whole blood samples
from chronic HBV patients were stained for CD14 and CD16 to analyze frequencies of the monocyte CD14++CD162 and CD14+CD16+ subpopulations.
(A) Gating strategy: monocytes were identified on the basis of their forward-sideward scatter, and divided into CD14++CD16- and CD14+CD16+
populations. (B) The frequencies of monocyte subpopulations were compared between groups 1–3 (n = 45).
doi:10.1371/journal.pone.0097006.g003
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and levels of viral proteins did not influence the functionality of the
monocyte compartment, suggesting that mechanisms are in place
to prevent in vivo activation of monocytes by viral proteins such as
HBsAg.
The majority of chronic HBV patients who are not being
treated have relatively high levels of HBsAg in serum. We showed
that monocytes are responsive to HBsAg, and get activated as a
consequence of in vitro exposure to HBsAg as evidenced by the
release of IL-6 and TNF. In agreement with our observations,
others have demonstrated that patient-derived HBsAg induced the
production of TNF and IL-10 by monocytes [16], and that
monocyte-derived DC produced IL-12 upon stimulation with
HBsAg [25]. However, there is controversy on the effect of
HBsAg, since it was also reported that HBV, HBeAg and HBsAg
are inhibitory and can in some cases suppress TLR-induced
cytokine production in various cell types [26–30], including
monocytes in vitro [31] and in vivo [13]. Importantly, using the same
preparation of HBsAg, we previously demonstrated suppression of
TLR9-induced IFN-a by plasmacytoid DC as a consequence of
exposure to HBsAg [29]. Furthermore, to rule out that the
Figure 4. Monocytes from different patient groups display similar TLR-induced cytokine production. PBMC from patients with distinct
HBV DNA, HBeAg and HBsAg profiles were incubated overnight with medium, Pam3CSK4, LPS or R848 to investigate the in vivo effect of HBV DNA
levels, HBeAg levels and HBsAg levels on monocyte function. (A) Gating strategy: viable monocytes were identified on the basis of their forward-
sideward scatter profile, and subsequently CD14+ monocytes were gated to assess cytokine production by intracellular cytokine staining (n = 45). (B,
left) The frequencies of monocytes producing IL-6 and TNF upon medium or TLR ligand stimulation were compared between groups 1–3. (B, right)
Representative dot-plots showing cytokine-positive cells induced by medium and R848 in one patient. (C) The cytokine levels measured in
supernatant by ELISA (in ng/ml) upon stimulation of PBMC were compared between patient groups 1–3 (n = 30).
doi:10.1371/journal.pone.0097006.g004
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stimulatory effects on monocytes were unique for the preparation,
we tested different preparations from different suppliers and
showed that the stimulatory capacity of HBsAg on monocytes was
a general feature (rHBsAg (Prospec, Rehovot, Israel), pHBsAg
Adr, pHBsAg Ayw (both Jena Bioscience GmbH, Jena, Germany),
data not shown). This could mean that monocytes contribute to
the initiation phase of an anti-viral immune response against
HBV, being able to recognize the viral envelope protein and
produce pro-inflammatory cytokines in the periphery, and possibly
also in the liver during inflammation.
Since the HBsAg concentrations that were used for in vitro
stimulations are in the same range as found in the serum of
chronic HBV patients (5 mg/ml HBsAg corresponding to
622,000 IU/ml HBsAg) [32], and since monocytes have been
shown to interact in vivo with HBsAg [33], one might expect that
this has a profound effect on the monocyte compartment in
patients. Consequently, it is expected that patients with distinct
levels of serum HBsAg, but also of HBV DNA and HBeAg,
demonstrate an altered monocyte phenotype and function. Our
findings show that the distribution of CD14++CD16- and
CD14+CD16+ monocytes was not different between patients with
distinctive virological characteristics. Our findings appear not be
in agreement with a study by Zhang et al., which showed increased
numbers of CD16+ monocytes in immune-active HBeAg-positive
patients as compared to healthy individuals or immunotolerant
patients [12]. It should be noted that monocyte subset frequencies
correlate with ALT values in chronic HBV patients [12], and that
the study by Zhang et al, and ours differ considerably with respect
to the ALT ranges included (13-1656 versus 15–443 IU/L).
Therefore, differences in inclusion criteria of patients to address
the respective research questions may likely explain the results.
Additionally, we showed that also the functionality, as demon-
strated by the frequency of TLR-induced cytokine producing
monocytes and the TLR-induced cytokine production in PBMC
was comparable in chronic HBV patients with different levels of
viral DNA and viral proteins. This important finding on limited
modulation of the monocyte compartment in chronic HBV
patients in vivo is not reflected by the immunostimulatory effect
of HBsAg on monocytes in vitro, and clearly demonstrates that
comparison of the in vivo and in vitro findings is complex. It is also
important to note that reported findings on the effects of HBsAg
on immune cells use other cell types or cell lines than primary
monocytes and different recombinant or plasma-derived prepara-
tions of HBsAg, which complicates the interpretation of the in vitro
findings [26-31,34]. Our findings are in line with Gehring et al.,
who showed that despite a constant exposure to HBsAg, ex vivo–
Figure 5. Monocytes from patients and healthy controls are
equally sensitive to HBsAg in vitro. PBMC from healthy individuals
or HBV patients with distinct in vivo exposure histories to HBV DNA,
HBeAg and HBsAg (group 3) were stimulated with HBsAg and the
relative frequency of cytokine-producing monocytes was determined
(n = 5–6). In the box-whisker plots, the line in the middle of the box is
the median, while the whiskers depict the minimum and the maximum
value.
doi:10.1371/journal.pone.0097006.g005
Figure 6. IL-10 inhibits the frequency of monocytes producing
cytokines upon HBsAg exposure. PBMC from healthy individuals
were stimulated with HBsAg, with or without IL-10. After overnight
incubation, cells were stained for CD14 and intracellularly for cytokines.
The frequencies of IL-6-positive (A) and TNF-positive (B) monocytes
were compared between HBsAg and HBsAg and IL10 (n = 3).
doi:10.1371/journal.pone.0097006.g006
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isolated monocytes did not constitutively activate HBV-specific
CD8+ T cells [33] Evaluation of monocytes from chronic HBV
patients showed that the induction of cytokines upon TLR ligation
was not affected by the clinical phase. Furthermore, the
spontaneous cytokine release of these monocytes was similar
between all groups, suggesting that the continuous exposure to
variable concentrations of HBV DNA, HBeAg or HBsAg did not
result in modulation of the ex vivo activation state of these cells.
Combined these findings suggest that the monocyte compart-
ment of patients is not affected as a consequence of exposure to
different concentrations of viral proteins and HBV DNA in serum.
Since this is in apparent conflict with the in vitro experiments in
which monocytes were exposed to HBsAg, it is tempting to
speculate that regulatory and/or compensatory mechanisms are in
place in vivo, which prevent excessive activation of monocytes by
serum HBsAg. We demonstrated that it is unlikely that unrespon-
siveness of patients’ monocytes to HBsAg due to desensitization as
a consequence of recent exposure to the same protein may explain
the discrepancy between the in vitro and in vivo observations, since
monocytes from patients are similarly responsive to HBsAg as
monocytes from healthy individuals, as shown by dose titrations.
However, a likely candidate that may contribute to explain the in
vivo data is the immunosuppressive cytokine IL-10 since it has been
reported that chronic HBV patients have increased serum IL-10
levels [18–22]. Our data indeed show that IL-10 is able to inhibit
cytokine production by HBsAg-induced monocytes, suggesting a
possible role of IL-10 in restraining pro-inflammatory cytokine
production by monocytes in HBV patients with high levels of
HBsAg, HBeAg and HBV DNA. However, also other candidate
molecules present in serum, such as TGF-b may further regulate
monocyte function in chronic HBV patients.
In summary, we demonstrate that HBsAg has potent stimula-
tory effects on monocytes in vitro. However, in chronic HBV
patients, the functionality of the monocyte compartment is not
influenced by variations in the levels of serum viral components,
suggesting that regulatory mechanisms are in place to prevent
excessive in vivo activation of monocytes.
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Figure S1 Monocytes from patients and healthy con-
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healthy individuals or HBV patients with distinct in vivo exposure
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recombinant HBsAg and the frequency of cytokine-producing
monocytes was determined (n= 5–6). In the box-whisker plots, the
line in the middle of the box is the median, while the whiskers
depict the minimum and the maximum value.
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